亚洲一区二区三区看片,日韩欧美九九九久久久,精品国产日韩亚洲一区在线,久久噜噜噜久久熟女精品

掃碼關注公眾號           掃碼咨詢技術支持           掃碼咨詢技術服務
  
客服熱線:400-901-9800  客服QQ:4009019800  技術答疑  技術支持  質(zhì)量反饋  人才招聘  關于我們  聯(lián)系我們
日韩精品一区二区三区在线观看视频,中文字幕本久久精品一区,91精品欧美一区二区三区综合
首頁 > 產(chǎn)品中心 > 標記一抗 > 產(chǎn)品信息
Rabbit Anti-KMT2A/Biotin Conjugated antibody (bs-16790R-Bio)
訂購熱線:400-901-9800
訂購郵箱:sales@www.lalhoau.cn
訂購QQ:  400-901-9800
技術支持:techsupport@www.lalhoau.cn
說 明 書: 100ul  
100ul/2980.00元
大包裝/詢價
產(chǎn)品編號 bs-16790R-Bio
英文名稱1 Rabbit Anti-KMT2A/Biotin Conjugated antibody
中文名稱 生物素標記的急性淋巴細胞性白血病1抗體
別    名 Acute lymphocytic leukemia 1; ALL 1; ALL-1; ALL1; C-terminal cleavage product of 180 kDa; CXXC 7; CXXC-type zinc finger protein 7; CXXC7; HRX; HTRX 1; HTRX1; KMT2A; Lysine N-methyltransferase 2A; MLL 1A; Mll; MLL cleavage product C180; MLL1; MLL1_HUMAN; MLL1A; Myeloid/lymphoid or mixed lineage leukemia; N-terminal cleavage product of 320 kDa; p180; p320; Trithorax homolog; Trithorax homolog Drosophila; Trithorax like protein; Trithorax-like protein; TRX 1; TRX1; Zinc finger protein HRX.  
規(guī)格價格 100ul/2980元 購買        大包裝/詢價
說 明 書 100ul  
研究領域 腫瘤  細胞生物  免疫學  淋巴細胞  t-淋巴細胞  b-淋巴細胞  表觀遺傳學  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應 (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, )
產(chǎn)品應用 ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200 IF=1:50-200 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 432kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human KMT2A
亞    型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
This gene encodes a transcriptional coactivator that plays an essential role in regulating gene expression during early development and hematopoiesis. The encoded protein contains multiple conserved functional domains. One of these domains, the SET domain, is responsible for its histone H3 lysine 4 (H3K4) methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. This protein is processed by the enzyme Taspase 1 into two fragments, MLL-C and MLL-N. These fragments reassociate and further assemble into different multiprotein complexes that regulate the transcription of specific target genes, including many of the HOX genes. Multiple chromosomal translocations involving this gene are the cause of certain acute lymphoid leukemias and acute myeloid leukemias. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Oct 2010]

Function:
Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis.

Subcellular Location:
Nucleus and Nucleus. Localizes to a diffuse nuclear pattern when not associated with MLL cleavage product N320.

Tissue Specificity:
Heart, lung, brain and T- and B-lymphocytes.

Post-translational modifications:
Proteolytic cleavage by TASP1 generates MLL cleavage product N320 and MLL cleavage product C180, which reassemble through a non-covalent association. 2 cleavage sites exist, cleavage site 1 (CS1) and cleavage site 2 (CS2), to generate MLL cleavage products N320 and C180. CS2 is the major site.

DISEASE:
Note=Chromosomal aberrations involving MLL are a cause of acute leukemias. Translocation t(1;11)(q21;q23) with MLLT11/AF1Q; translocation t(3;11)(p21;q23) with NCKIPSD/AF3p21; translocation t(3,11)(q25,q23) with GMPS; translocation t(4;11)(q21;q23) with AFF1/MLLT2/AF4; insertion ins(5;11)(q31;q13q23) with AFF4/AF5Q31; translocation t(5;11)(q12;q23) with AF5-alpha/CENPK; translocation t(6;11)(q27;q23) with MLLT4/AF6; translocation t(9;11)(p22;q23) with MLLT3/AF9; translocation t(10;11)(p11.2;q23) with ABI1; translocation t(10;11)(p12;q23) with MLLT10/AF10; t(11;15)(q23;q14) with CASC5 and ZFYVE19; translocation t(11;17)(q23;q21) with MLLT6/AF17; translocation t(11;19)(q23;p13.3) with ELL; translocation t(11;19)(q23;p13.3) with MLLT1/ENL; translocation t(11;19)(q23;p23) with GAS7; translocation t(X;11)(q13;q23) with FOXO4/AFX1. Translocation t(3;11)(q28;q23) with LPP. Translocation t(10;11)(q22;q23) with TET1. Translocation t(9;11)(q34;q23) with DAB2IP. Translocation t(4;11)(p12;q23) with FRYL. Fusion proteins MLL-MLLT1, MLL-MLLT3 and MLL-ELL interact with PPP1R15A and, on the contrary to unfused MLL, inhibit PPP1R15A-induced apoptosis.

Similarity:
Belongs to the histone-lysine methyltransferase family.
TRX/MLL subfamily.
Contains 3 A.T hook DNA-binding domains.
Contains 1 bromo domain.
Contains 1 CXXC-type zinc finger.
Contains 1 FY-rich C-terminal domain.
Contains 1 FY-rich N-terminal domain.
Contains 3 PHD-type zinc fingers.
Contains 1 post-SET domain.
Contains 1 SET domain.

Database links:

Entrez Gene: 4297 Human

Entrez Gene: 214162 Mouse

Omim: 159555 Human

SwissProt: Q03164 Human

SwissProt: P55200 Mouse

Unigene: 258855 Human

Unigene: 2389 Mouse



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
版權(quán)所有 2004-2026 www.www.lalhoau.cn 北京博奧森生物技術有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號
瑞金市| 英超| 西昌市| 繁昌县| 肇州县| 石门县| 集贤县| 克拉玛依市| 正定县| 丹阳市| 广德县| 兖州市| 宁强县| 鹿邑县| 太仓市| 汾西县| 怀来县| 富顺县| 永善县| 乐都县| 泰州市| 池州市| 巩留县| 海阳市| 睢宁县| 西吉县| 泰州市| 阜宁县| 灵宝市| 寻甸| 阿拉善左旗| 图木舒克市| 左云县| 沂南县| 江山市| 汝州市| 阿巴嘎旗| 通河县| 凉山| 英吉沙县| 双流县|